Table 3.

Risk for any cardiovascular toxicity by therapy received

	Anthracycline only					VEGF inhibitor only					Anthracycline + VEGF inhibitor
	Unadjusted			Adjusted		Unadjusted			Adjusted		Unadjusted			Adjusted
	N	HR	95% CI	HR	95% CI	N	HR	95% CI	HR	95% CI	N	HR	95% CI	HR	95% CI
Age at first therapya		1.01	(0.99–1.03)	1.02	(1.00–1.04)		1.00	(0.95–1.05)	1.00	(0.95–1.05)		1.01	(0.95–1.07)	1.02	(0.96–1.09)
Gender
Female	105	ref.		ref.		20	ref.		ref.		9	ref.		ref.
Male	131	1.34	(1.04–1.73)	1.4	(1.08–1.81)	20	1.19	(0.64–2.20)	1.18	(0.63–2.20)	13	1.66	(0.71–3.91)	2.35	(0.93–5.92)
Race
White	190	ref.		ref.		34	ref.		ref.		17	ref.		ref.
Non-white	46	1.04	(0.75–1.44)	1.04	(0.75–1.43)	6	0.95	(0.40–2.27)	0.97	(0.41–2.33)	5	2.6	(0.95–7.11)	4.04	(1.35–12.12)
Comorbidities prior to therapyb
Hypertension	15	1.09	(0.65–1.84)	1.06	(0.62–1.82)	0	-		-		0	-		-
Diabetes	6	1.44	(0.64–3.24)	1.42	(0.63–3.21)	0	-		-		0	-		-
Dyslipidemia	8	0.81	(0.40–1.64)	0.75	(0.37–1.54)	2	1.27	(0.30–5.28)	1.27	(0.30–5.36)	2	2.77	(0.62–12.33)	3.54	(0.77–16.35)

Adjusted for age at first therapy, gender, race and comorbidities diagnosed prior to initiation of therapy

^aHazard ratios calculated using age at first therapy as a continuous variable per one year increment

^bReference group: patients without respective comorbidity prior to treatment